Precision cancer imaging market seen growing to $31.71B by 2030

The Business Research Company says the precision cancer imaging market will rise from $19.58 billion in 2026 to $31.71 billion by 2030, as cancer cases climb and hospitals adopt more advanced imaging tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the next few years.

Why it matters: - Precision cancer imaging is becoming more important as cancer rates rise and providers look for earlier detection and more personalized treatment planning. - The market’s growth signals stronger demand for molecular imaging, PET and MRI systems, and AI-enabled diagnostic tools. - The forecast points to a larger global shift toward precision medicine and less invasive cancer diagnostics.

What happened: - The Business Research Company released a 2026 report on the global precision cancer imaging market. - The market is projected to grow from $17.39 billion in 2025 to $19.58 billion in 2026. - The report forecasts the market will reach $31.71 billion by 2030. - The report places the market’s 2025-2026 CAGR at 12.6% and the 2026-2030 CAGR at 12.8%. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa.

The details: - Precision cancer imaging combines targeted imaging methods to detect, characterize and monitor cancer at earlier stages. - The approach uses molecular imaging, functional imaging and high-resolution anatomical imaging. - The market’s recent growth has been driven by rising cancer cases, advances in molecular imaging, broader PET and MRI adoption, improved hospital diagnostic infrastructure and government-backed screening programs. - Future growth is expected to come from demand for personalized oncology treatments, AI-powered imaging analytics, precision medicine research, cloud-based imaging platforms and less invasive diagnostic techniques. - The report highlights wider use of precision oncology imaging, hybrid imaging systems, multi-modal diagnostic workflows, radiomics for tumor characterization and improved early cancer detection. - The report says its 2026 editions now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The Business Research Company offers a free sample of the report and the full report through its website: Download a free sample and View the full report.

Between the lines: - The report ties market demand to a structural rise in cancer incidence, not just near-term technology adoption. - WHO projected in February 2024 that new cancer cases could top 35 million by 2050, up 77% from about 20 million in 2022. - That kind of long-range growth helps explain why imaging vendors and healthcare systems are investing in more advanced diagnostic workflows now.

What's next: - The market is expected to keep expanding as hospitals and cancer centers add precision imaging tools and AI-assisted analytics. - Regional momentum is likely to stay strongest in Asia-Pacific as healthcare spending and cancer burden rise. - The next competitive phase will likely center on hybrid systems, radiomics and cloud-based imaging platforms.

The bottom line: - Precision cancer imaging is moving from a specialized capability to a core part of oncology care, and the market outlook reflects that shift.